NURS FPX 8004 Assessment 1 Professional Practice Report

Professional Practice Report

Student name

Capella University

NURS-FPX8004

Professor Name

Submission Date

Section I: Application of the MEAL Plan

Pulmonary hypertension (M) is a severe medical condition whereby the blood pressure in the blood vessels that supply blood to and out of the heart and lungs is brought to an abnormally high level, and hence the blood circulation process becomes compromised.

(E)Normally, in a healthy physiological state, the blood moves through the right ventricle of the heart to the lungs at a low pressure due to the low distance to be covered. Pulmonary hypertension causes the constriction of the pulmonary vessels, and this reduction of blood flow is accompanied by a reduction of the amount of oxygen that gets into the blood. The health condition normally goes hand-in-hand with other health issues and is normally experienced by individuals of all ages, but mostly by women, the elderly, and certain ethnic groups.

(A) Symptoms related to pulmonary hypertension include a number of nonspecific symptoms of the disease in the initial stages of the disease. Consequently, the pulmonary hypertension can be diagnosed at late stages of progression. During the initial phases, there is fatigue and dyspnea. When the pulmonary hypertension reaches a more advanced stage, more serious manifestations include chest pain, dizziness, ankle swelling, heart palpitations, etc.

(L). Even though pulmonary hypertension has not yet had a definite cure, preventive measures and treatment of pulmonary hypertension involve minimizing the symptoms and avoiding complications. Anti-swelling medication, oral medication, inhaled medication, and oxygen therapy are all used in managing symptoms of pulmonary hypertension in a patient.

Defining Pulmonary arterial hypertension Pulmonary arterial hypertension is a progressive vascular disorder whereby the stress levels in the right side of the heart are increased as a result of high blood pressure in the lungs, thus causing heart failure in the long run. Taking into consideration the fact that, in the past, pulmonary arterial hypertension was linked with very poor survival rates, Shah et al. (2023) emphasized that the results of this medical condition have significantly improved with the development of pharmacological treatment.

The recent therapeutic approaches in treating pulmonary arterial hypertension include the use of pharmacological agents, which are vascular pathology agents, such as the endothelin antagonists, nitric oxide, and the prostacyclin analogues. Nevertheless, pulmonary arterial hypertension remains a life-threatening disease where morbidity and mortality rates are high, and it is of great importance to keep on with research to identify viable treatment modalities to enhance long-term survival rates of patients afflicted with the disease.

Section II: Practice Site and Problem

The organization belongs to a local healthcare system and offers the entire medical care to the population of the region (Executive Nurse, personal communication, February 15, 2026). The environment is mainly dedicated to the diagnosis and treatment of chronic cardiopulmonary diseases, including pulmonary hypertension, chronic obstructive pulmonary disease, and heart failure. The team has physicians, nurse practitioners, registered nurses, and respiratory therapists, among other healthcare professionals, who collaborate in the care provision to the patients.

The organization offers care to a varied population of various socioeconomic statuses. Most of the patients in the clinic have chronic health issues and need to be handled in the long run (Executive Nurse, personal communication, February 15, 2026). The organization has adopted the use of an electronic record system that offers patient care and documentation. The organizational culture aims at patient-centered care and teamwork in delivering effective care to patients using evidence-based practice (Executive Nurse, personal communication, February 15, 2026). The leaders within the clinic are helpful in introducing quality improvement programs aimed at fulfilling the gaps in patient care to enhance the effectiveness of the interventions given.

Practice Problem Analysis and Significance

The major issue found in the practice site is the latent identification or diagnosis of pulmonary hypertension in patients with initial signs or symptoms of cardiopulmonary diseases. The issue was determined by informal review or observation of the healthcare providers of the practice site (Executive Nurse, personal communication, February 15, 2026). Nonspecific signs or symptoms may manifest in the form of dyspnea, fatigue, reduced exercise tolerance, etc., and patients present with them often.

The signs or symptoms can be similar to those of other heart and lung diseases, and thus repeated clinic visits may be necessary or may take a long time before the relevant investigations or procedures can be referred (Executive Nurse, personal communication, February 15, 2026). The process or duration in which patients receive the proper investigations to test pulmonary hypertension or cardiopulmonary diseases has been identified by healthcare givers at the practice site as a potential issue.

This issue has an interesting practice gap because the early-stage identification of pulmonary hypertension plays a critical role in the initiation of the right approach and control of pulmonary hypertension. It has been shown that pulmonary arterial hypertension is a disease that is difficult to diagnose, and in the event of late diagnosis, the disease leads to inappropriate outcomes and deterioration of the right ventricular activity.

As an example, one of the recent studies discovered that the late diagnosis of the condition leads to poor outcomes within the patient group as opposed to the patients diagnosed with the condition earlier (Kubota et al., 2023). According to nationwide research, patients diagnosed with the condition of pulmonary arterial hypertension spend over two years between the onset of symptoms and the real diagnosis, primarily due to being mistaken for having other respiratory issues (Rosenberg, 2023). The disparity subsequently results in ill health conditions of the patients.

The identified gap in the practice site is not a solitary problem, but rather a problem on a bigger scale on the national level in regard to early diagnosis of pulmonary hypertension. The patient survey outcomes and clinical studies have revealed that many patients consult a number of various medical providers before they get the right diagnosis for the condition. There are instances where more than half of the patients take over one year to get the diagnosis of pulmonary hypertension despite the individual noticing the symptoms (Pulmonary Hypertension Association UK, 2023). Consequently, patients have poor outcomes and a poor prognosis of the disease.

There are also profound clinical, financial, and systemic effects of the delayed diagnosis of pulmonary hypertension. The research conducted to assess the patterns of healthcare service usage has discovered that late-diagnosis cases are characterized by high rates of hospitalization, extended care unit stays, and higher healthcare expenses in comparison with patients with early diagnosis (Weiss et al., 2024).

Delayed diagnosis was identified in an economic study to be linked to higher monthly healthcare expenditures and readmission rates to the hospital (DuBrock et al., 2023). The effects of the latter impact negatively on the quality of life and the healthcare system in general and can result in the further development of the disease, which would have been prevented with the early identification and intervention.

For the next (2nd) Assessment of this class visit: NURS FPX 8004 Assessment 2